SCHEMBL11943666

SCHEMBL11943666

CS(=O)(=O)c1ccc(-c2c(N3CCN(S(=O)(=O)Cc4ccccc4)CC3)cnn(-c3cc(F)cc(F)c3)c2=O)cc1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.46
▸ PTGS2 P35354 7/20 0.46
▸ ALDH1A1 P00352 3/20 0.43
▸ DCTPP1 Q9H773 1/20 0.43
▸ POLB P06746 1/20 0.42
▸ CYP3A4 P08684 1/20 0.42
▸ CYP2C19 P33261 1/20 0.42
▸ PPARG P37231 1/20 0.42
▸ NCOA2 Q15596 1/20 0.42
▸ NCOA1 Q15788 1/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42
▸ NCOA3 Q9Y6Q9 1/20 0.42
▸ PTGS1 P23219 3/20 0.40
▸ LMNA P02545 1/20 0.39
▸ NR1H2 P55055 1/20 0.38
▸ NR1H3 Q13133 1/20 0.38
▸ MAPK1 P28482 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11943749 0.92 MAPT (0.48) MAPTPTGS2ALDH1A1DCTPP1POLB
SCHEMBL11943720 0.92 MAPT (0.48) MAPTALDH1A1DCTPP1POLBCYP3A4
SCHEMBL11943746 0.92 MAPT (0.48) MAPTALDH1A1DCTPP1POLBCYP3A4
SCHEMBL11943638 0.92 MAPT (0.49) MAPTALDH1A1DCTPP1POLBCYP3A4
SCHEMBL11943734 0.92 MAPT (0.45) MAPTPTGS2ALDH1A1DCTPP1POLB
SCHEMBL11943559 0.91 MAPT (0.48) MAPTALDH1A1DCTPP1POLBCYP3A4
SCHEMBL11943656 0.91 MAPT (0.49) MAPTALDH1A1DCTPP1POLBCYP3A4
SCHEMBL11943708 0.90 MAPT (0.49) MAPTALDH1A1DCTPP1POLBCYP3A4
SCHEMBL11943730 0.90 MAPT (0.46) MAPTALDH1A1DCTPP1POLBCYP3A4
SCHEMBL11943663 0.90 MAPT (0.50) MAPTALDH1A1DCTPP1POLBCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA MAPT 2295/4885PTGS2 1342/4885ALDH1A1 2437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback